ʻO Tetrabenzyl Dapagliflozin CAS: 2001088-28-2

Hoʻohui ʻia ma o nā ʻano hana organik kūikawā, hōʻike ka tetrabenzyl dapagliflozin i kahi hoʻolālā molekala paʻakikī koʻikoʻi no kāna mau noi like ʻole. ʻO ke alo o ʻehā mau mea hoʻohui benzyl ma ke kumu dapagliflozin e hoʻopili i kāna hana kemika, ka solubility, a me nā pilina me nā ʻōnaehana olaola. He mea nui kēia mau ʻano kūkulu no ka hoʻomaopopo ʻana i kāna ʻano pharmacological a me ka hiki ke therapeutic. Nā noi ma nā lāʻau lapaʻau Paʻa kēia hui i ka hoʻohiki i ka noiʻi lāʻau lapaʻau ma muli o kona ʻano kūkulu. Hoʻohana ʻia nā derivatives Dapagliflozin, i ʻike ʻia no ko lākou kuleana ma ke ʻano he sodium-glucose co-transporter 2 (SGLT2) inhibitors, i ka mālama ʻana i ka maʻi diabetes mellitus type 2. Hiki i nā benzyl substitutions ma tetrabenzyl dapagliflozin ke hoʻololi i kona mau waiwai pharmacokinetic a hoʻonui paha i kona koho a me ka pono ma ke ʻano he mea hoʻopaʻa SGLT2. Hana Olaola a me nā ʻano Hana Hōʻike nā haʻawina e hoʻopuka ʻo dapagliflozin a me kāna mau derivatives i kā lākou hopena therapeutic ma ka pale ʻana iā SGLT2 i loko o nā tubules proximal renal, no laila e hōʻemi ana i ka reabsorption glucose renal a hoʻonui i ka excretion glucose urinary. Hiki i nā hui benzyl ma ka tetrabenzyl dapagliflozin ke hoʻololi i kona ikaika, kūpaʻa metabolic, a i ʻole nā ​​​​​​launa me nā mea loaʻa ma waho o ka pahuhopu, e hoʻopilikia ana i kāna ʻano pharmacological holoʻokoʻa. Nā Alanui Synthetic a me ka Hoʻomohala ʻana ʻO ka synthesis o tetrabenzyl dapagliflozin e pili ana i nā kaʻina hana organik paʻakikī e hoʻomaka ana mai dapagliflozin a me benzyl halides a i ʻole benzyl alcohols. He mea nui ka hoʻonui ʻana i nā ala synthetic no ka hoʻokō ʻana i ka maʻemaʻe kiʻekiʻe a me nā hua, pono no nā noi lāʻau lapaʻau. Eia kekahi, hoʻomaikaʻi ka hoʻomaʻemaʻe ʻana i nā ala synthesis i ka scalability, cost-effectiveness, a me ka hoʻomau ʻana i ka hana ʻana i nā lāʻau lapaʻau. Noiʻi o kēia manawa a me nā kuhikuhi e hiki mai ana Ke kālele nei nā hana noiʻi o kēia manawa i ka ʻimi ʻana i ka hiki o ka tetrabenzyl dapagliflozin ma mua o ka mālama ʻana i ka maʻi diabetes, me kāna noi ʻana i nā maʻi cardiovascular a i ʻole nā ​​​​​​maʻi metabolic. Hiki i nā haʻawina e hiki mai ana ke noiʻi i nā hoʻololi i kona ʻano e hoʻomaikaʻi i ka bioavailability, hoʻemi i nā hopena ʻaoʻao, a i ʻole e kuhikuhi i nā ala therapeutic hou aʻe. Ke hoʻomau nei nā hoʻokolohua lapaʻau a me nā haʻawina preclinical e loiloi i kona palekana, pono, a me nā hopena lōʻihi. Hopena I ka hopena, hōʻike ʻo tetrabenzyl dapagliflozin i kahi hui kaulana i ka kemika lāʻau lapaʻau a me ka noiʻi lāʻau lapaʻau ma muli o kona ʻano kemika ʻokoʻa a me nā noi therapeutic hiki. ʻO ka hoʻohui ʻana o ʻehā mau hui benzyl i loko o ka ʻōnaehana dapagliflozin e hōʻike ana i kona versatility a me ka hoʻohiki pharmacological, ʻoi aku hoʻi i nā maʻi e like me ka type 2 diabetes mellitus. ʻO ka hoʻolaha ʻana i ka noiʻi i kāna mau waiwai kemika, nā pilina olaola, a me nā ʻano hana synthetic he mea nui ia no ka hoʻonui ʻana i kona hiki ke therapeutic a me ka hoʻonui ʻana i kāna mau noi i ka lāʻau lapaʻau.